SCHEMBL16474587

SCHEMBL16474587

Cc1cc(=O)n(-c2ccc(OC(F)(F)F)cc2)cc1-c1ccc(F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MCHR1 Q99705 2/20 0.39
▸ PTGS2 P35354 4/20 0.39
▸ FFAR4 Q5NUL3 4/20 0.39
▸ FFAR1 O14842 2/20 0.39
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ SCN5A Q14524 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ PPARD Q03181 2/20 0.35
▸ PPARA Q07869 2/20 0.35
▸ PPARG P37231 1/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ P2RY1 P47900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474584 0.90 PTGS2 (0.39) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474588 0.90 FFAR4 (0.40) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474612 0.88 MCHR1 (0.43) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16479449 0.88 MCHR1 (0.43) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474582 0.86 PTGS2 (0.41) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474586 0.85 MAPT (0.47) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474554 0.84 MCHR1 (0.41) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL16474581 0.84 PTGS2 (0.41) KDM4EGAAMAPTMAPK1MCHR1
SCHEMBL18077707 0.84 MAPK14 (0.38) MCHR1PTGS2PDE3BPDE3A
SCHEMBL16474635 0.82 POLB (0.41) KDM4EGAAMAPTMAPK1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 — — EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 — — US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 — — US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 — — US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 — — US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 — — US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 — — US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 — — US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 — — US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 — — US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 — — US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 — — US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 — — US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 — — US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 — — US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 — — WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 — — US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback